Anebulo Pharmaceuticals
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.anebulo.com
- Introduction
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)โข Click on a phase to view related trials
I.V. Selonabant in Healthy Adult Subjects
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT07211607
- Locations
- ๐บ๐ธ
PPD Austin Clinical Research Unit, Austin, Texas, United States
Observational Study of THC Concentrations in Acute Cannabinoid Intoxication
- Conditions
- Acute Cannabinoid Intoxication
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT06017622
- Locations
- ๐บ๐ธ
University of Colorado School of Medicine, Aurora, Colorado, United States
๐บ๐ธHenry Ford Hospital, Detroit, Michigan, United States
๐บ๐ธOakland University William Beaumont School of Medicine, Royal Oak, Michigan, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Anebulo Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT05282797
- Locations
- ๐ณ๐ฑ
Centre for Human Drug Research (CHDR), Leiden, ZH, Netherlands
News
Anebulo Pharmaceuticals Initiates Phase I Trial of IV Selonabant as First Cannabis Toxicity Antidote
Anebulo Pharmaceuticals has begun dosing participants in a Phase I trial of intravenous selonabant, targeting acute cannabis-induced toxicity with NIDA funding support.